Metastatic Urothelial Cancer Clinical Trial
Official title:
A Single-arm, Open-label, Multi-center Phase 2 Study of Enfortumab Vedotin (ASG-22CE) in Chinese Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy (EV-203)
The purpose of this study was to determine the antitumor activity of enfortumab vedotin (EV) confirmed by the objective response rate (ORR). This study also evaluated the effect of antibody-drug conjugate (ADC), total antibody (TAb) and monomethyl auristatin E (MMAE) in Chinese participants with locally advanced or metastatic urothelial cancer. In addition, the study also evaluated the duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and immunogenicity determined by the incidence of antitherapeutic antibodies (ATA). Safety and tolerability of EV in participants with locally advanced or metastatic urothelial cancer was also evaluated.
This study comprised of a single group of participants who received one dose of enfortumab vedotin (EV) on Days 1, 8 and 15 of every 4-week (28 days) cycle. Participants continued on study treatment until discontinuation. After treatment discontinuation, participant had an end of treatment (EOT) visit for a 30-day Safety Follow-up. Participants to discontinue to treatment for reasons other than disease progression were followed for response assessments. A Pharmacokinetic (PK) cohort was available at some study centers. Participants enrolled at the PK cohort site(s) had intense PK samples collected after single and repeated doses. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03682068 -
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
|
Phase 3 | |
| Recruiting |
NCT05101096 -
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02826564 -
Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer
|
Phase 1 | |
| Completed |
NCT01963052 -
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05390645 -
A Study of MFA-370 in Patients With Metastatic Urothelial Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03745911 -
Paclitaxel and TAK-228 in Urothelial Carcinoma
|
Phase 2 | |
| Completed |
NCT03390595 -
Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma
|
Phase 2 | |
| Completed |
NCT03451331 -
Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
|
Phase 2 | |
| Completed |
NCT03679767 -
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
|
Phase 2 | |
| Recruiting |
NCT06225596 -
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
|
Phase 2/Phase 3 | |
| Completed |
NCT02240017 -
A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03547973 -
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
|
Phase 2 | |
| Completed |
NCT03070990 -
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 1 | |
| Completed |
NCT03448718 -
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
|
Phase 2 |